28
Tue, Mar
10 New Articles

Ardelyx, Inc. a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases announced the initiation of a Phase 3 clinical trial and an onset-of-action clinical trial evaluating RDX7675 in patients with hyperkalemia, a potentially life-threatening condition common in patients with cardiorenal disease.

ContraVir Pharmaceuticals, Inc a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies announced that the company was awarded a $297,875 CAD research grant from the National Research Council in Canada through the Council's Industrial Research Assistance Program (IRAP).

More Articles ...

Sign up via our free email subscription service to receive notifications when new information is available.
captcha